|
KMID : 0360319920240020256
|
|
Journal of Korean Cancer Research Association
1992 Volume.24 No. 2 p.256 ~ p.267
|
|
|
A Prospective Randomized Study of Cisplatin Versus PEV(Cisplatin, Etoposide, Vinblastine) Chemotherapy in Advanced Non-Small Cell Lung Cancer
|
|
이기형
강원기/장정순/윤성수/임영혁/이재용/박영석/서창인/허대석
|
|
|
Abstract
|
|
|
One hundred and twenty-seven patients with unresectable non-small cell lung cancer were included in a randomized trial comparing the activity of cisplatin as a single agent with the combination of cisplatin, etoposide, and vinblastine(PEV). All
patients
were previously untreated and prognostic factors(performance status, weight loss, extent of disease, and histology) were evenly distributed between two study groups. In 115 evaluable patients(54 for cisplatin alone and 61 combined regimen), the
only
complete responder was PEV combination(p=0.051). The median time to progression for patients treated with cisplatin alone was 22 weeks, which was significantly longer than 13 weeks for patients treated with PEV regiment(p=0.0001). No
statistically
significant difference in survival was observed between the patients treated with cisplatin alone and those treated with combined regimen(median survival; 8 v 11 months). In the PEV arm the median survival was 14 months for patients with ECOG
performance status of 0-1, compared with 3.4 months for those with ECOG performace status of 2(p=0.0001), and 14 months for patients without previous weight loss, compared with 8.4 months for those with previous weight loss(p=0.04).
Myelosuppression was
greater with the combination, but with regards to non-hematologic toxicity, there was no significant difference between two arms except for alopecia which occured more frequently in patients treated with combined regimen. The results indicate
that
the
combination of cisplatin, etoposide, and vinblastine is superior to cisplatin alone in terms of response rate and the time to progression in non-small cell lung cancer, but confers no significant survival advantage compared with cisplatin alone
in
spite
of greater degree of myelosuppression.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
 
|
|